Antiandrogen therapy in hidradenitis suppurativa: finasteride for females.

Autor: Babbush KM; Department of Medicine, Division of Dermatology, Albert Einstein College of Medicine, Bronx, New York, NY, USA., Andriano TM; Department of Medicine, Division of Dermatology, Albert Einstein College of Medicine, Bronx, New York, NY, USA., Cohen SR; Department of Medicine, Division of Dermatology, Albert Einstein College of Medicine, Bronx, New York, NY, USA.
Jazyk: angličtina
Zdroj: Clinical and experimental dermatology [Clin Exp Dermatol] 2022 Jan; Vol. 47 (1), pp. 86-92. Date of Electronic Publication: 2021 Aug 31.
DOI: 10.1111/ced.14847
Abstrakt: Background: Given its widely accepted efficacy, androgen blockade therapy for hidradenitis suppurativa (HS) has become a standard of care. Although much less frequently used than spironolactone, a small number of HS studies have reported finasteride as an alternative treatment for women. In this study, we describe the response to and perception of finasteride therapy in a diverse cohort of women with HS.
Aim: To describe finasteride therapy in a diverse cohort of female patients with HS.
Methods: We conducted an institutional review board-approved retrospective chart review and telephone survey of 20 female patients aged ≥ 18 years with a diagnosis of HS. Finasteride was prescribed by a single provider at a specialized HS centre.
Results: The mean age of the patients was 34.3 ± 13.5 years. Finasteride was initiated predominantly because of one or more contraindications or poor responsiveness to spironolactone. Most patients interviewed (90%; n = 18) were willing to take finasteride again or continue with therapy if indicated. Of the 20 patients, 10 (50%) reported overall satisfaction with finasteride, while 7 (35%) were neutral and 3 (15%) were dissatisfied. No patient reported worsening disease activity while on finasteride and only one (5%) reported decreased quality of life. When asked about adverse effects of finasteride, 80% (n = 16) reported none, while 20% (n = 4) experienced ≥ 1 of the following: headache, nausea, menstrual irregularities, breast tenderness or reduced libido/sexual function.
Conclusions: Our study suggests that androgen blockade therapy with finasteride is a safe and effective alternative for female patients with HS who have contraindication(s) or intolerance to spironolactone.
(© 2021 British Association of Dermatologists.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje